<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-8705</journal-id>
<journal-title><![CDATA[CES Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[CES Med.]]></abbrev-journal-title>
<issn>0120-8705</issn>
<publisher>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-87052017000100058</article-id>
<article-id pub-id-type="doi">10.21615/cesmedicina.31.1.6</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Incompatibilidad de medicamentos intravenosos: revisión estructurada]]></article-title>
<article-title xml:lang="en"><![CDATA[Incompatibility of intravenous drugs: Structured review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Madrigal-Cadavid]]></surname>
<given-names><![CDATA[Juliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>31</volume>
<numero>1</numero>
<fpage>58</fpage>
<lpage>69</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-87052017000100058&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-87052017000100058&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-87052017000100058&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Las incompatibilidades físicas o químicas presentadas entre las mezclas de medicamentos de uso intravenosos pueden comprometer la eficacia y seguridad del tratamiento y del paciente. La disponibilidad de la información relacionada con este aspecto es limitada o fraccionada, lo que restringe su uso. El objetivo del presente trabajo fue sistematizar la información disponible en las bases de datos sobre compatibilidad/incompatibilidad entre medicamentos intravenosos, que favorezca los procesos de prescripción, preparación y administración.  Métodos: Revisión estructurada de incompatibilidades de medicamentos intravenosos en PubMed/MedLine utilizando los términos MeSH: Drug Incompatibility, Administration Intravenous, and Infusions Intravenous. Se buscaron artículos en inglés o español, con acceso a texto completo hasta febrero 29 del 2016. Se identificaron 121 artículos, de los cuales se seleccionaron 58; además se incluyeron 18 manuscritos de las referencias considerados como importantes.  Resultados: Se estructuró un cuadro sobre compatibilidad/incompatibilidad de 100 medicamentos intravenosos, el tiempo de estabilidad, condiciones de almacenamiento, tipo de compatibilidad/incompatibilidad presentada y tipo de administración recomendada.  Conclusión: Se presenta información sobre compatibilidad / incompatibilidad de medicamentos, la cual podría favorecer los procesos de prescripción, preparación y administración por el personal asistencial y con ello contribuir a la efectividad y seguridad de estos medicamentos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: The physical or chemical incompatibilities between mixtures of intravenous drugs may compromise the efficacy and safety of treatment and the patient. The availability of information related to this aspect is limited or fractionated, which restricts its use; in this context. The objective of the present study was to compile in a table the available information in the databases on the compatibility/incompatibility between intravenous drugs, which favors the processes of prescription, preparation and administration of these products.  Methods:  We completed a structured review of incompatibilities of intravenous drugs in PubMed/Medline using the MeSH terms: Drug Incompatibility, Administration Intravenous, and Infusions Intravenous, we collected articles in English or Spanish, with access to full text until February 29, 2016. We identified 121 articles, from which we selected 58; additionally we included 18 manuscripts of the references considered as important.  Results:  With the information obtained was structured a table on compatibility/incompatibility of 100 intravenous drugs, the time of stability, conditions of storage, type of compatibility/incompatibility presented and the type of management recommended.  Conclusion:  We arranged information on compatibility/incompatibility of drugs, which may improve the processes of prescription, preparation and administration by the health care professionals, so it could contribute to the effectiveness and safety of these drugs.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Incompatibilidad de medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Administración intravenosa]]></kwd>
<kwd lng="es"><![CDATA[Infusiones intravenosas]]></kwd>
<kwd lng="en"><![CDATA[Drug Incompatibility]]></kwd>
<kwd lng="en"><![CDATA[Intravenous administration]]></kwd>
<kwd lng="en"><![CDATA[Intravenous infusions]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Incompatibilities in intravenous therapy: What can be done to prevent them?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Secoli]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Esquirol]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[de Las Heras Matellán]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vendrell Bosh]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ballarín Alins]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Enferm Clin]]></source>
<year>2009</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>349-53</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Recomendaciones para la preparación de medicamentos estériles en las unidades de enfermería]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín de Rosales Cabrera]]></surname>
<given-names><![CDATA[A.M]]></given-names>
</name>
<name>
<surname><![CDATA[López Cabezas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pernía López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dávila Pousa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vila Clérigues]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso Herreros]]></surname>
<given-names><![CDATA[J.M]]></given-names>
</name>
</person-group>
<source><![CDATA[Farm Hosp]]></source>
<year>2014</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-64</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[voiding common perils of drug administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenthal]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Nursing]]></source>
<year>2007</year>
<volume>37</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>20-1</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Preventing Incompatibility in I.V. Admixtures]]></article-title>
<source><![CDATA[Nursing]]></source>
<year>1980</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>48-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#8220;Hidden dangers&#8221;]]></article-title>
<source><![CDATA[Br J Anaesth]]></source>
<year>1971</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>109</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Contaminated drip fluid]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stuttaford]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Br Med J]]></source>
<year>1972</year>
<volume>3</volume>
<page-range>112</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development of a compatibility chart for intravenous Y-site drug administration in a pediatric intensive care unit]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manrique Rodríguez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Galindo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mora-García]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez-Llamazares]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Echarri-Martínez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[López-Herce]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[J Infus Nurs]]></source>
<year>2012</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>109-14</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of commonly used intravenous infusions in a pediatric intensive care unit]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wedekind]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Fidler]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Care Nurse]]></source>
<year>2001</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>45-51</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Blocking i.v. drug incompatibilities]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Nursing]]></source>
<year>1993</year>
<volume>23</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>74</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Voytilla]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Tyler]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Rusho]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2002</year>
<volume>59</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>853-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baririan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chanteux]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Viaene]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Servais]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tulkens]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2003</year>
<volume>51</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>651-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berti]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Hutson]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Schulz]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2015</year>
<volume>72</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>390-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Dedhiya]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[DiNunzio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kupiec]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2011</year>
<volume>68</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2163-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of ceftazidime and aminophylline admixtures for different methods of intravenous infusion]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pleasants]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Vaughan]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1992</year>
<volume>26</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1221-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Servais]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tulkens]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2001</year>
<volume>45</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2643-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility and stability of ceftazidime sodium and tenoxicam in 5 % dextrose injection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Chiou]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2004</year>
<volume>61</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1924-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kupiec]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Gole]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jimidar]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2008</year>
<volume>65</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1545-51</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elmore]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Contois]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Noe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Poirier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Ther]]></source>
<year>1996</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>246-55</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical and chemical compatibility of intravenous ciprofloxacin with other drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jim]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1993</year>
<volume>27</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>704-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical and chemical compatibility of daptomycin with nine medications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brodeur]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2004</year>
<volume>38</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1612-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of doripenem with other drugs during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brammer]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Heatherly]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Trusley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kupiec]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2008</year>
<volume>65</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1261-5</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability and compatibility of reconstituted ertapenem with commonly used i.v. infusion and coinfusion solutions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McQuade]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Van Nostrand]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Schariter]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kanike]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Forsyth]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2004</year>
<volume>61</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-45</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Incompatibility of imipenem-cilastatin and amoxicillin]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pourroy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bausset]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Boulamery]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Villano]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Braguer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2009</year>
<volume>66</volume>
<page-range>14</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canann]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tyler]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Barker]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Condie]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2009</year>
<volume>66</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>727-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability and compatibility of levofloxacin and metronidazole during simulated and actual Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sprandel]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Styrczula]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Deyo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sibley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodvold]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2005</year>
<volume>62</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>88-92</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of levofloxacin injection and magnesium sulfate]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klang]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2009</year>
<volume>66</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1520</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ofloxacin intravenous. Compatibility with other antibacterial agents]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Janknegt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Stratermans]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cilissen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lohman]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hooymans]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharm Weekbl Sci]]></source>
<year>1991</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>207-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2010</year>
<volume>67</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1640-4</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate lock solutions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[LaPlante]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Woodmansee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mermel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2012</year>
<volume>69</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1405-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Housman]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Tessier]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolau]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Kuti]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2011</year>
<volume>68</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2265-70</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Venkatesan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ly]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Scheetz]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2013</year>
<volume>70</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1163-6</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Condie]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Tyler]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Barker]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Canann]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2008</year>
<volume>65</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>454-7</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability of zidovudine with oxytocin in a simulated Y-site injection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bushman]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2004</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>394-6</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical and chemical compatibility of injectable acetaminophen during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Boehme]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ouellette]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stidham]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mackay]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Hosp Pharm]]></source>
<year>2014</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42-7</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of butorphanol and droperidol in 0.9 % sodium chloride injection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[BX]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2013</year>
<volume>70</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>515-9</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physico-chemical stability of butorphanol-tramadol and butorphanol-fentanyl patient-controlled analgesia infusion solutions over 168 hours]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmazie]]></source>
<year>2014</year>
<volume>69</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>585-8</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vecuronium bromide and methylprednisolone succinate are physically incompatible]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prabhakar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Rath]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Sheikh]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Neurosurg Anesthesiol]]></source>
<year>2008</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>153-4</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Standardization of infusion solutions to reduce the risk of incompatibility]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nemec]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kopelent Frank]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Greif]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2008</year>
<volume>65</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1648-54</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kambia]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Luyckx]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dine]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dupin Spriet]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gressier]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Brunet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Pharm Ther]]></source>
<year>2009</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25- 31</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term stability of tramadol chlorhydrate and metoclopramide hydrochloride in dextrose 5 % polyolefin bag at 4 degrees C]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Athanasopoulos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hecq]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Vanbeckbergen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jamart]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Galanti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[J Oncol Pharm Pract]]></source>
<year>2009</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>195-200</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foushee]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Gormley]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Lineberger]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2015</year>
<volume>72</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>483-6</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of ketamine hydrochloride and fentanyl citrate in polypropylene syringes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ambados]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Brealey]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2004</year>
<volume>61</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1438- 45</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Propofol compatibility with other intravenous drug products: two new methods of evaluating IV emulsion compatibility]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michaels]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Stauffer]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1996</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>228-32</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Drug compatibility differences with propofol injectable emulsion products]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Care Med]]></source>
<year>2001</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>466-8</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nemec]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Germ]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schulz Siegmund]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ortner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmazie]]></source>
<year>2009</year>
<volume>64</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>94-7</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability of sufentanil and levobupivacaine solutions and a mixture in a 0.9 % sodium chloride infusion stored in polypropylene syringes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jäppinen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Turpeinen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kokki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rasi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ojanen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pelkonen]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Pharm Sci]]></source>
<year>2003</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-6</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ribas Nicolau]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Amorós Cerdá]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo Rubert]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maqueda Palau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Enferm Intensiva]]></source>
<year>2011</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>78-82</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Administración compatible de la terapia intravenosa continúa en el paciente coronario crítico]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amorós Cerdá]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Maqueda Palau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ribas Nicolau]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo Rubert]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Enferm Cardiol]]></source>
<year>2013</year>
<volume>20</volume>
<numero>58</numero>
<issue>58</issue>
<page-range>46-9</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Visual compatibility of clonidine with selected drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veggeland]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2005</year>
<volume>62</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1968-9</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaaf]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tremel]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Wulf]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Vernon]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Pharm Ther]]></source>
<year>1990</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>371-6</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newland]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Mauro]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2009</year>
<volume>66</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>986-7</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility of milrinone lactate injection with intravenous drugs commonly used in the pediatric intensive care unit]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veltri]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Conner]]></surname>
<given-names><![CDATA[KG]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2002</year>
<volume>59</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>452-4</page-range></nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continúa]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Maqueda Palau]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arévalo Rubert]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ribas Nicolau]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Amorós Cerda]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[Enferm Intensiva]]></source>
<year>2010</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>96-103</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Visual compatibility of vasopressin with other injectable drugs.]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barker]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Feddema]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rusho]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dengg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2005</year>
<volume>62</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1975-6</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Visual compatibility of abciximab with selected drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baroletti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hartman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Churchill]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2002</year>
<volume>59</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>466-7</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of argatroban with abciximab, eptifibatide, or tirofiban during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hursting]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health-Syst Pharm]]></source>
<year>2005</year>
<volume>62</volume>
<page-range>1381-4</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Visual compatibility of argatroban with selected drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartman]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Baroletti]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Churchill]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2002</year>
<volume>59</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1784-5</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility of 4 % sodium citrate with selected antimicrobial agents]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dotson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lynn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Savakis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Churchwell]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2010</year>
<volume>67</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1195-8</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Demmon]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Boelk]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Payne]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Effron]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Rajagopalan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2004</year>
<volume>61</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2664-71</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Tawfik]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Saxinger]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Stang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Etches]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Antimicrob Chemother]]></source>
<year>2005</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>951-3</page-range></nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergquist]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Hunke]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Manas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Forsyth]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kenney]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Pharm Ther]]></source>
<year>1999</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>125-32</page-range></nlm-citation>
</ref>
<ref id="B62">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility of calcium gluconate and magnesium sulfate injections]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beauregard]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bertrand]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dufour]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Blaizel]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Leclair]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2012</year>
<volume>69</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>98</page-range></nlm-citation>
</ref>
<ref id="B63">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility of magnesium sulfate and sodium bicarbonate in a pharmacy-compounded hemofiltration solution]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moriyama]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Henning]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kolf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rehak]]></surname>
<given-names><![CDATA[NN]]></given-names>
</name>
<name>
<surname><![CDATA[Danner]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2010</year>
<volume>67</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>562-5</page-range></nlm-citation>
</ref>
<ref id="B64">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of conivaptan injection with select cardiovascular medications]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Boddu]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Mauro]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
<name>
<surname><![CDATA[Churchwell]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2014</year>
<volume>71</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1534-5</page-range></nlm-citation>
</ref>
<ref id="B65">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schaller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Placek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Duersch]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Chemother Pharmacol]]></source>
<year>2013</year>
<volume>72</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>509-13</page-range></nlm-citation>
</ref>
<ref id="B66">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bougouin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thelcide]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Crespin Maillard]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Maillard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kinowski]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Favier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2005</year>
<volume>62</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2001-5</page-range></nlm-citation>
</ref>
<ref id="B67">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kupie]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Trusley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ben]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2008</year>
<volume>65</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1735-59</page-range></nlm-citation>
</ref>
<ref id="B68">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Trusley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ben]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kupiec]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2007</year>
<volume>64</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1209-13</page-range></nlm-citation>
</ref>
<ref id="B69">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[QA]]></given-names>
</name>
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2004</year>
<volume>61</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1596-8</page-range></nlm-citation>
</ref>
<ref id="B70">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability, compatibility and plasticizer extraction of quinine injection added to infusion solutions and stored in polyvinyl chloride (PVC) containers]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faouzia]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Khalfia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Dinea]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Luyckxa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bruneta]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gressiera]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pharm Biomed Anal]]></source>
<year>1999</year>
<volume>21</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>923-30</page-range></nlm-citation>
</ref>
<ref id="B71">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusión]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chevrier]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sautou]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pinon]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Demeocq]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chopineau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharm Acta Helv]]></source>
<year>1995</year>
<volume>70</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>141-8</page-range></nlm-citation>
</ref>
<ref id="B72">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozdemir]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Anilanmert]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pekin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Chemother Pharmacol]]></source>
<year>2005</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>529-34</page-range></nlm-citation>
</ref>
<ref id="B73">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Compatibility and stability of paclitaxel combined with doxorubicin hydrochloride in infusion solutions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[QA]]></given-names>
</name>
<name>
<surname><![CDATA[Gilbert]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1998</year>
<volume>32</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1013-6</page-range></nlm-citation>
</ref>
<ref id="B74">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trissel]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Saenz]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Ogundele]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Ingram]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2004</year>
<volume>61</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2289-93</page-range></nlm-citation>
</ref>
<ref id="B75">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Nolt]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2003</year>
<volume>60</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>193-4</page-range></nlm-citation>
</ref>
<ref id="B76">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cochran]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Sowinski]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Fausel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Overholser]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2007</year>
<volume>64</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1410-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
